Key TakeawaysEli Lilly will acquire Ventyx Biosciences for $1.2 billion to develop oral therapies for inflammatory-mediated diseases.The acquisition highlights the industry’s focus on inflammation as a driver of chronic diseases.Ventyx’s pipeline includes NLRP3 inhibitors targeting cardiometabolic, neurodegenerative, and autoimmune conditions.The transaction is expected to close in the first half of 2026, following regulatory approvals and […]
